News

FOR A NUMBER OF YEARS the MGH Cancer Center has been at the forefront of the promising field of targeted therapy, in which treatment is tailored to attack specific genetic mutations responsible for an individual patient’s tumor. A major gift of $10 million from Henri and Belinda Termeer, announced Sept. 13, will enable the Cancer Center to expand its efforts in this area through the creation of the Henri and Belinda Termeer Center for Targeted Therapies.

New hope for cancer patients

Milestone gift establishes Henri and Belinda Termeer Center for Targeted Therapies

16/Sep/2011

TRANSFORMING CARE: From left, Baselga, Henri and Belinda
Termeer, Peter L. Slavin, MD, MGH president, and Haber

FOR A NUMBER OF YEARS the MGH Cancer Center has been at the forefront of the promising field of targeted therapy, in which treatment is tailored to attack specific genetic mutations responsible for an individual patient’s tumor. A major gift of $10 million from Henri and Belinda Termeer, announced Sept. 13, will enable the Cancer Center to expand its efforts in this area through the creation of the Henri and Belinda Termeer Center for Targeted Therapies. The former chief executive of Genzyme Corporation, Henri has been a longtime supporter of the MGH and serves on the MGH Board of Trustees. Also an active member of the hospital community, Belinda is a director on the MGH Cancer Center Leadership Council.

“Henri and Belinda’s gift is incredibly generous and all the more important to us since it comes from two exceptional individuals who are so committed to and knowledgeable about the field of personalized cancer therapies,” says Daniel Haber, MD, PhD, director of the Cancer Center. “This is a real endorsement for us and a milestone for the Cancer Center.”

José Baselga, MD, PhD, chief of Hematology/Oncology and associate director of the MGH Cancer Center, will lead the new Termeer Center, which will be located on the seventh floor of the Yawkey Center for Outpatient Care. The Termeer Center will feature a translational research program to speed the discovery and delivery of new targeted therapies to patients with early- and advanced-stage cancer, significantly expanding the number and range of clinical trials available to patients.

“This support will benefit patients and their loved ones for many years to come,” says Baselga. “We are tremendously excited about the new center and the pioneering work that will come out of it. The field of cancer care and research is in the midst of a sea change. There is so much more hope we can offer with the possibilities of this new personalized approach. I find it especially inspiring to be at MGH, the place that is doing so much of the most important work in the field.”

The Termeers’ gift is one of the largest donations dedicated to cancer treatment in MGH history. For more information about the Henri and Belinda Termeer Center for Targeted Therapies, access www.massgeneral.org/targetedtherapy

patient

U.S. News and World Report Best Hospitals 2013-2014

U.S. News & World Report ranks Mass General #2 in the nation and #1 in New England based on our quality of care, patient safety and reputation in 16 clinical specialties.

Search the Mass General news archive

Search the archive for previously published news articles, press releases and publications.

View all departments

Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.